Infectious diseases are illnesses caused by pathogenic microorganisms—including viruses, bacteria, fungi, and parasites—that invade a host, replicate, and ...
Structure Therapeutics CEO discusses oral GLP-1 strategy, Phase 3 plans, and why pills and combination therapies may reshape obesity treatment.
Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best up and coming stocks to buy according to Wall Street. On December 19, H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target ...
Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...
Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote bar is ...
Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...
Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...